Citigroup’s Kindred Biosciences, Inc. KIN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-247,219
| Closed | -$2.27M | – | 6535 |
|
|
2021
Q2 | $2.27M | Buy |
247,219
+244,634
| +9,464% | +$1.42M | ﹤0.01% | 2573 |
|
|
2021
Q1 | $13K | Sell |
2,585
-4,897
| -65% | -$23.7K | ﹤0.01% | 5517 |
|
|
2020
Q4 | $32K | Buy |
7,482
+5,573
| +292% | +$22.7K | ﹤0.01% | 6360 |
|
|
2020
Q3 | $8K | Sell |
1,909
-3,168
| -62% | -$13.2K | ﹤0.01% | 6800 |
|
|
2020
Q2 | $23K | Sell |
5,077
-6,205
| -55% | -$27.7K | ﹤0.01% | 6527 |
|
|
2020
Q1 | $45K | Buy |
11,282
+3,123
| +38% | +$26.5K | ﹤0.01% | 6068 |
|
|
2019
Q4 | $69K | Buy |
8,159
+3,732
| +84% | +$29.1K | ﹤0.01% | 6073 |
|
|
2019
Q3 | $30K | Sell |
4,427
-5,950
| -57% | -$43.6K | ﹤0.01% | 6487 |
|
|
2019
Q2 | $87K | Buy |
10,377
+567
| +6% | +$4.89K | ﹤0.01% | 5999 |
|
|
2019
Q1 | $90K | Buy |
9,810
+2,181
| +29% | +$22.1K | ﹤0.01% | 5851 |
|
|
2018
Q4 | $83K | Sell |
7,629
-908
| -11% | -$11.4K | ﹤0.01% | 5822 |
|
|
2018
Q3 | $119K | Buy |
8,537
+7,998
| +1,484% | +$108K | ﹤0.01% | 5733 |
|
|
2018
Q2 | $6K | Sell |
539
-30,468
| -98% | -$297K | ﹤0.01% | 7323 |
|
|
2018
Q1 | $268K | Buy |
31,007
+29,848
| +2,575% | +$262K | ﹤0.01% | 4647 |
|
|
2017
Q4 | $11K | Buy |
1,159
+1,082
| +1,405% | +$8.45K | ﹤0.01% | 7007 |
|
|
2017
Q3 | $1K | Sell |
77
-82,115
| -100% | -$616K | ﹤0.01% | 7189 |
|
|
2017
Q2 | $707K | Buy |
+82,192
| New | +$590K | ﹤0.01% | 3659 |
|
|
2016
Q1 | – | Sell |
-442
| Closed | -$2K | – | 7902 |
|
|
2015
Q4 | $2K | Buy |
+442
| New | +$2.05K | ﹤0.01% | 7306 |
|
|
2015
Q3 | – | Sell |
-18
| Closed | – | – | 7890 |
|
|
2015
Q2 | $0 | Sell |
18
-556
| -97% | -$3.94K | ﹤0.01% | 7864 |
|
|
2015
Q1 | $4K | Sell |
574
-1,226
| -68% | -$8.45K | ﹤0.01% | 6811 |
|
|
2014
Q4 | $13K | Buy |
1,800
+1,435
| +393% | +$12.2K | ﹤0.01% | 6392 |
|
|
2014
Q3 | $3K | Buy |
365
+276
| +310% | +$3.73K | ﹤0.01% | 6754 |
|
|
2014
Q2 | $2K | Buy |
89
+44
| +98% | +$747 | ﹤0.01% | 6806 |
|
|
2014
Q1 | $1K | Sell |
45
-39
| -46% | -$744 | ﹤0.01% | 6910 |
|
|
2013
Q4 | $1K | Buy |
+84
| New | +$1K | ﹤0.01% | 6896 |
|
Other funds holding KIN
Citigroup's KIN Position: Q3 2021 in Review
Citigroup sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 247,219 shares — an estimated $2.27M sold.
Citigroup first reported a position in KIN in Q4 2013 and held it in 25 quarters. The position peaked at $2.27M in Q2 2021. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.
- Citigroup reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
- Citigroup sold 247,219 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $2.27M.
- Citigroup first reported a position in Kindred Biosciences, Inc. in Q4 2013 and held it in 25 quarters.
- Citigroup's Kindred Biosciences, Inc. position peaked at $2.27M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.
Based on Citigroup's 13F filing for Q3 2021, filed 10 Nov 2021.